Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach-;demonstrated in mouse models and isolated human brain tissue-;to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction – Biotech Investments

MorphoSys AG / Key word(s): Study results Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction

November 21, 2023

Oregon suspends a portion of its drug transparency law found to be unconstitutional

In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a contentious state law designed to bring more transparency to prescription

February 23, 2024

MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001 | Psychedelic Invest

MindBio Therapeutics Corp. reported durability data from Phase 2A clinical trials in depressed patients testing MB22001, MindBio’s proprietary self-administered take home microdose of Lysergic Acid

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.